About arGEN-X BV (NASDAQ:ARGX)
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$18.98 million
Price / Sales135.10
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
arGEN-X BV (NASDAQ:ARGX) Frequently Asked Questions
What is arGEN-X BV's stock symbol?
arGEN-X BV trades on the NASDAQ under the ticker symbol "ARGX."
Where is arGEN-X BV's stock going? Where will arGEN-X BV's stock price be in 2018?
4 brokerages have issued 1-year price objectives for arGEN-X BV's shares. Their forecasts range from $41.00 to $100.00. On average, they expect arGEN-X BV's stock price to reach $76.00 in the next twelve months. View Analyst Ratings for arGEN-X BV.
Who are some of arGEN-X BV's key competitors?
Some companies that are related to arGEN-X BV include Swedish Orphan Bio (SWTUY), AveXis (AVXS), United Therapeutics (UTHR), Orion (ORINY), Blueprint Medicines (BPMC), Integra Lifesciences (IART), FibroGen (FGEN), Indivior (INVVY), ABLYNX (ABLYF), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), Hikma Pharmaceutic (HKMPF), Advanced Accelerator Application (AAAP), Ligand Pharmaceuticals (LGND), Array Biopharma (ARRY), TESARO (TSRO), ACADIA Pharmaceuticals (ACAD) and Halozyme Therapeutics (HALO).
Who are arGEN-X BV's key executives?
arGEN-X BV's management team includes the folowing people:
- Mr. Tim Van Hauwermeiren MSc, EMBA, CEO & Exec. Director (Age 46)
- Mr. Eric Castaldi, Chief Financial Officer (Age 54)
- Prof. Hans de Haard Ir, Ph.D., Chief Scientific Officer (Age 58)
- Dr. Torsten Dreier Ph.D., Chief Devel. Officer (Age 54)
- Dr. Debbie Allen Ph.D., Sr. VP of Bus. Devel. (Age 58)
When did arGEN-X BV IPO?
(ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Has arGEN-X BV been receiving favorable news coverage?
Media coverage about ARGX stock has been trending somewhat positive this week, according to Accern. The research firm identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. arGEN-X BV earned a news impact score of 0.06 on Accern's scale. They also assigned news stories about the company an impact score of 44.86 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of arGEN-X BV?
Shares of ARGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is arGEN-X BV's stock price today?
One share of ARGX stock can currently be purchased for approximately $79.71.
How big of a company is arGEN-X BV?
arGEN-X BV has a market capitalization of $2.59 billion and generates $18.98 million in revenue each year. arGEN-X BV employs 67 workers across the globe.
How can I contact arGEN-X BV?
arGEN-X BV's mailing address is Willemstraat 5, Breda P7, 4811 AH. The company can be reached via phone at 329-310-3400 or via email at [email protected]
MarketBeat Community Rating for arGEN-X BV (ARGX)MarketBeat's community ratings are surveys of what our community members think about arGEN-X BV and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for arGEN-X BV (NASDAQ:ARGX)
No earnings announcements for this company have been tracked by MarketBeat.com
arGEN-X BV (NASDAQ:ARGX) Earnings Estimates
2018 EPS Consensus Estimate: ($2.73)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for arGEN-X BV (NASDAQ:ARGX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for arGEN-X BV (NASDAQ ARGX)
No insider trades for this company have been tracked by MarketBeat.com
arGEN-X BV (NASDAQ ARGX) News Headlines
arGEN-X BV (NASDAQ:ARGX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
arGEN-X BV (NASDAQ:ARGX) Income Statement, Balance Sheet and Cash Flow Statement
arGEN-X BV (NASDAQ ARGX) Stock Chart for Thursday, March, 22, 2018